{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T05:12:23Z","timestamp":1784265143747,"version":"3.55.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T00:00:00Z","timestamp":1696204800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.jcf.2023.09.013","type":"journal-article","created":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T09:25:47Z","timestamp":1696497947000},"page":"214-218","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Impact of highly effective modulator therapy on chronic rhinosinusitis and health status: 2-year follow-up"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8612-5442","authenticated-orcid":false,"given":"Daniel M.","family":"Beswick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aastha","family":"Khatiwada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9769-187X","authenticated-orcid":false,"given":"Jessa E.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5113-4530","authenticated-orcid":false,"given":"Stephen M.","family":"Humphries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7157-7462","authenticated-orcid":false,"given":"Alexandra","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eszter K.","family":"Vladar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Taylor-Cousar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.jcf.2023.09.013_bib0001","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"10212","key":"10.1016\/j.jcf.2023.09.013_bib0002","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jcf.2023.09.013_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2023.02.004","article-title":"Elexacaftor\/tezacaftor\/ivacaftor projected survival and long-term health outcomes in people with cystic fibrosis homozygous for F508del","author":"Lopez","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"7","key":"10.1016\/j.jcf.2023.09.013_bib0004","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/alr.22332","article-title":"Clinical predictors of cystic fibrosis chronic rhinosinusitis severity","volume":"9","author":"Zemke","year":"2019","journal-title":"Int Forum Allergy Rhinol"},{"issue":"8","key":"10.1016\/j.jcf.2023.09.013_bib0005","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1177\/00034894211045636","article-title":"Association of quality of life measures and otolaryngologic care in cystic fibrosis patients","volume":"131","author":"Leong","year":"2022","journal-title":"Ann Otol Rhinol Laryngol"},{"issue":"12","key":"10.1016\/j.jcf.2023.09.013_bib0006","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/alr.21607","article-title":"The sino-nasal outcome test-22 as a tool to identify chronic rhinosinusitis in adults with cystic fibrosis","volume":"5","author":"Habib","year":"2015","journal-title":"Int Forum Allergy Rhinol"},{"issue":"1","key":"10.1016\/j.jcf.2023.09.013_bib0007","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1513\/AnnalsATS.202101-057OC","article-title":"Impact of cystic fibrosis transmembrane conductance regulator therapy on chronic rhinosinusitis and health status: deep learning CT analysis and patient-reported outcomes","volume":"19","author":"Beswick","year":"2022","journal-title":"Ann ATS"},{"issue":"3","key":"10.1016\/j.jcf.2023.09.013_bib0008","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jcf.2020.07.002","article-title":"Effect of highly effective modulator treatment on sinonasal symptoms in cystic fibrosis","volume":"20","author":"DiMango","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.09.013_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2022.03.002","article-title":"Elexacaftor-Tezacaftor- Ivacaftor improves sinonasal outcomes in cystic fibrosis","author":"Stapleton","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"11","key":"10.1016\/j.jcf.2023.09.013_bib0010","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/alr.23016","article-title":"Objective and patient-based measures of chronic rhinosinusitis in people with cystic fibrosis treated with highly effective modulator therapy","volume":"12","author":"Beswick","year":"2022","journal-title":"Int Forum Allergy Rhinol"},{"issue":"11","key":"10.1016\/j.jcf.2023.09.013_bib0011","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1002\/alr.22588","article-title":"Volumetric assessment of paranasal sinus opacification on computed tomography can be automated using a convolutional neural network","volume":"10","author":"Humphries","year":"2020","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jcf.2023.09.013_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2023.03.002","article-title":"Real-world safety and effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: interim results of a long-term registry-based study","volume":"22","author":"Bower","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.jcf.2023.09.013_bib0013","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/alr.21668","article-title":"Twenty-two-item sino-nasal outcome test in a control population: a cross-sectional study and systematic review","volume":"6","author":"Farhood","year":"2016","journal-title":"Int Forum Allergy Rhinol"},{"issue":"6","key":"10.1016\/j.jcf.2023.09.013_bib0014","first-page":"1197","article-title":"Health related utility measurement: an introduction","volume":"22","author":"Bakker","year":"1995","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.jcf.2023.09.013_bib0015","first-page":"110","article-title":"Responsiveness and minimal clinically important difference for the EQ-5D in chronic rhinosinusitis","volume":"57","author":"Hoehle","year":"2019","journal-title":"Rhinology"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199323009177?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199323009177?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T08:22:51Z","timestamp":1772353371000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199323009177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S1569199323009177"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2023.09.013","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of highly effective modulator therapy on chronic rhinosinusitis and health status: 2-year follow-up","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2023.09.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}